Brief: Madrigal Pharmaceuticals Q4 EPS USD -2.71
26/02/2025 12:00
Feb 26 (Reuters) - Madrigal Pharmaceuticals Q4 net income USD -59.416 million. Q4 operating expenses USD 170.317 million Q4 operating income USD -66.997 million
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)